GlaxoSmithKline, Daiichi Sankyo join forces to sell vaccines in Japan

GlaxoSmithKline ($GSK) and Daiichi Sankyo ($D4S.BE) will jointly invest about $1.2 million and pool their vaccine operations into a 50/50 joint venture that they expect will be largest vaccine company in Japan. The Wall Street Journal points out that Japan's market has good growth potential because it currently uses many older vaccines and because the population is only beginning to vaccinate against some conditions that traditionally have been treated symptomatically. The deal is expected to be completed in the third quarter. Release | Story

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.